Johnson & Johnson Aktie News

Johnson & Johnson could become the second biopharma company to achieve $100 billion in annual sales. The healthcare leader has a robust and diversified business that can support its dividend program.

Johnson & Johnson: Fraud Claim Dismissal Today Is Not A Sign Talc Litigation Is Over

AMPLITUDE is the first clinical trial to evaluate potential therapies for patients with mHSPC and known HRR gene alterations, with positive results supporting the niraparib-based combination regimen as a new standard of care for patients with BRCA mutations 1

A U.S. district judge on Thursday dismissed a lawsuit alleging Johnson & Johnson committed fraud by repeatedly attempting to use a shell company's bankruptcy to resolve tens of thousands of lawsuits claiming its baby powder and other talc products caused cancer.

Susan Bao's large-cap JPMorgan fund has outperformed the S&P 500 over many years. She's bullish on stocks, focused on bargains.

Visa's terrific business should help support its dividend program. Johnson & Johnson has over 50 years of consecutive dividend growth.

Johnson & Johnson remains a buy as business momentum accelerates, with Q4 revenue up 9.1% YoY and strong U.S. sales resilience. Their deal with the Trump Administration eliminates tariffs in exchange for lower drug prices. This is expected to provide gross margin relief despite some remaining pressure. Guidance for 2026 calls for accelerating top-line growth and at least 50bps pre-tax operating...

Chevron operates in all three phases of the oil value chain. Procter & Gamble has increased its annual dividend for 69 consecutive years.